CN107047536A - 一种细胞保存液及其应用 - Google Patents
一种细胞保存液及其应用 Download PDFInfo
- Publication number
- CN107047536A CN107047536A CN201611046215.2A CN201611046215A CN107047536A CN 107047536 A CN107047536 A CN 107047536A CN 201611046215 A CN201611046215 A CN 201611046215A CN 107047536 A CN107047536 A CN 107047536A
- Authority
- CN
- China
- Prior art keywords
- cell
- preservation liquid
- acid
- chloride
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 30
- 238000004321 preservation Methods 0.000 title claims abstract description 29
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 24
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 12
- 239000011780 sodium chloride Substances 0.000 claims abstract description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 20
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 20
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 20
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 18
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 11
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 11
- HHGZUQPEIHGQST-RGVONZFCSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]propanoic acid;dihydrochloride Chemical compound Cl.Cl.OC(=O)[C@@H](N)CSSC[C@H](N)C(O)=O HHGZUQPEIHGQST-RGVONZFCSA-N 0.000 claims description 10
- 229920001503 Glucan Polymers 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 10
- 108010024636 Glutathione Proteins 0.000 claims description 10
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 10
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 10
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 10
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 10
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 10
- 239000004473 Threonine Substances 0.000 claims description 10
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 10
- 229960002685 biotin Drugs 0.000 claims description 10
- 235000020958 biotin Nutrition 0.000 claims description 10
- 239000011616 biotin Substances 0.000 claims description 10
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 10
- 229960002079 calcium pantothenate Drugs 0.000 claims description 10
- 229960000304 folic acid Drugs 0.000 claims description 10
- 235000019152 folic acid Nutrition 0.000 claims description 10
- 239000011724 folic acid Substances 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 235000013922 glutamic acid Nutrition 0.000 claims description 10
- 239000004220 glutamic acid Substances 0.000 claims description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 10
- 229960000367 inositol Drugs 0.000 claims description 10
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 10
- 229960000310 isoleucine Drugs 0.000 claims description 10
- 229930182817 methionine Natural products 0.000 claims description 10
- 229960003966 nicotinamide Drugs 0.000 claims description 10
- 235000005152 nicotinamide Nutrition 0.000 claims description 10
- 239000011570 nicotinamide Substances 0.000 claims description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 10
- 239000001103 potassium chloride Substances 0.000 claims description 10
- 235000011164 potassium chloride Nutrition 0.000 claims description 10
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 10
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 10
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 10
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 10
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 10
- 239000004474 valine Substances 0.000 claims description 10
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 9
- 235000019743 Choline chloride Nutrition 0.000 claims description 9
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 9
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 9
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 229960001230 asparagine Drugs 0.000 claims description 9
- 235000009582 asparagine Nutrition 0.000 claims description 9
- 229960003178 choline chloride Drugs 0.000 claims description 9
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 9
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 9
- 229960002591 hydroxyproline Drugs 0.000 claims description 9
- 229960005337 lysine hydrochloride Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229960002477 riboflavin Drugs 0.000 claims description 9
- 235000019192 riboflavin Nutrition 0.000 claims description 9
- 239000002151 riboflavin Substances 0.000 claims description 9
- 239000001509 sodium citrate Substances 0.000 claims description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 9
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 8
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 8
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- LFDGRWDETVOGDT-UHFFFAOYSA-N 1h-pyrrole;hydrochloride Chemical compound Cl.C=1C=CNC=1 LFDGRWDETVOGDT-UHFFFAOYSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 239000005864 Sulphur Substances 0.000 claims 2
- 235000015177 dried meat Nutrition 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 101150029234 Hes5 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 229930003270 Vitamin B Natural products 0.000 description 5
- 235000019156 vitamin B Nutrition 0.000 description 5
- 239000011720 vitamin B Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- NFIYTPYOYDDLGO-UHFFFAOYSA-N phosphoric acid;sodium Chemical compound [Na].OP(O)(O)=O NFIYTPYOYDDLGO-UHFFFAOYSA-N 0.000 description 2
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- 206010000125 Abnormal dreams Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- -1 acyl Amine Chemical class 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种细胞保存液及其应用。所述细胞保存液包括以下成分:IL‑2,10‑30U/ml,羟乙基淀粉5‑20mg/ml,氯化钠0.3‑10mg/ml,氯化镁0.1‑0.5mg/ml,余量为胎牛血清。本发明的细胞保存液可以有效保存免疫细胞。
Description
技术领域
本发明涉及一种细胞保存液及其应用。
背景技术
癌症是人类的噩梦,其危害与日俱增。世界卫生组织(WHO)报道,当前全世界每年新发现癌症病人约1200万,死亡600万,平均每天有1.7万人死于癌症,癌症已成为新世纪人类的第一杀手,并成为全球最大的公共卫生问题之一。我国的发病情况亦不容乐观,目前我国癌症发病人数每年250万~300万,根据中国***2008年发布的第三次全国死因调查显示,中国城乡居民的癌症死亡率在过去30年中增长了80%以上,每4位死亡人数中就有1位死于癌症。
目前手术、放疗和化疗是现代肿瘤治疗的三大常规方式,其在杀死肿瘤细胞的同时也会严重的损害患者的身体,且存在较大的复发风险,而肿瘤免疫治疗被誉为是绿色疗法,有效针对靶细胞,基本不损伤正常细胞,且复发风险较小。
免疫细胞治疗作为生物治疗中最重要的一类,主要是通过现代生物技术对从患者或者直系亲人中提取的免疫细胞进行体外处理,使其具有更强的活力和更大的数量,并回输到患者体内,达到增强患者免疫力以对抗或杀灭癌细胞的一种方法,其中细胞活性决定了该技术的有效性,现有的免疫细胞保存液基本都不能达到保持细胞活性的要求,只能极短暂保存或者液氮中保存,而这将严重影响细胞治疗的效果。
发明内容
本发明为了克服现有技术的至少一个不足,提供一种新的细胞保存液,可以有效保存免疫细胞。
为了实现上述目的,本发明采取下述技术方案来实现:
一种细胞保存液,包括以下成分:
IL-2,10-30U/ml,
羟乙基淀粉5-20mg/ml,
氯化钠0.3-10mg/ml,
氯化镁0.1-0.5mg/ml,
余量为胎牛血清。
进一步,所述细胞保存液还包括以下成分:
人血白蛋白0-8mg/ml、胱氨酸二盐酸盐0-0.1mg/ml、α-1,4葡聚糖0-1.5mg/ml、无水硫酸镁0-0.05mg/ml、无水磷酸二氢钠0.2-1mg/ml、氯化钾0-0.8mg/ml、葡萄糖0.2-5mg/ml、还原谷胱甘肽0-0.01mg/ml、谷氨酰胺0-0.5mg/ml、柠檬酸钠0-6mg/ml、精氨酸0-0.5mg/ml、门冬氨酸0-0.05mg/ml、谷氨酸0-0.05mg/ml、甘氨酸0-0.05mg/ml、组氨酸0-0.05mg/ml、羟脯氨酸0-0.05mg/ml、亮氨酸0-0.1mg/ml、核黄素0-0.005mg/ml、盐酸硫胺素0-0.005mg/ml、维生素B120-0.001mg/ml、赖氨酸盐酸盐0-0.1mg/ml、甲硫氨酸0-0.05mg/ml、苯丙氨酸0-0.05mg/ml、脯氨酸0-0.05mg/ml、丝氨酸0-0.05mg/ml、苏氨酸0-0.05mg/ml、色氨酸0-0.01mg/ml、酪氨酸0-0.05mg/ml、缬氨酸0-0.05mg/ml、对氨基苯甲酸0-0.01mg/ml、硝酸钙0-0.5mg/ml、生物素0-0.005mg/ml、泛酸钙0-0.005mg/ml、叶酸0-0.05mg/ml、肌醇0-0.05mg/ml、烟酰胺0-0.005mg/ml、氯化胆碱0-0.005mg/ml、异亮氨酸0-0.1mg/ml、盐酸吡哆醇0-0.005mg/ml、门冬酰胺0-0.1mg/ml。
进一步,所述细胞保存液的成分由以下组分组成:
IL-2,10-30U/ml,羟乙基淀粉10-15mg/ml,,氯化钠0.3-10mg/ml,氯化镁0.1-0.5mg/ml;人血白蛋白0.01-8mg/ml、胱氨酸二盐酸盐0.01-0.1mg/ml、α-1,4葡聚糖0.01-1.5mg/ml、无水硫酸镁0.01-0.05mg/ml、无水磷酸二氢钠0.2-1mg/ml、氯化钾0.01-0.8mg/ml、葡萄糖0.2-5mg/ml、还原谷胱甘肽0.001-0.01mg/ml、谷氨酰胺0.01-0.5mg/ml、柠檬酸钠0.01-6mg/ml、精氨酸0.01-0.5mg/ml、门冬氨酸0.01-0.05mg/ml、谷氨酸0.01-0.05mg/ml、甘氨酸0.01-0.05mg/ml、组氨酸0.01-0.05mg/ml、羟脯氨酸0.01-0.05mg/ml、亮氨酸0.01-0.1mg/ml、核黄素0.001-0.005mg/ml、盐酸硫胺素0.001-0.005mg/ml、维生素B120.0001-0.001mg/ml、赖氨酸盐酸盐0.01-0.1mg/ml、甲硫氨酸0.01-0.05mg/ml、苯丙氨酸0.01-0.05mg/ml、脯氨酸0.01-0.05mg/ml、丝氨酸0.01-0.05mg/ml、苏氨酸0.01-0.05mg/ml、色氨酸0.001-0.01mg/ml、酪氨酸0.01-0.05mg/ml、缬氨酸0.01-0.05mg/ml、对氨基苯甲酸0.001-0.01mg/ml、硝酸钙0.01-0.5mg/ml、生物素0.001-0.005mg/ml、泛酸钙0.001-0.005mg/ml、叶酸0.01-0.05mg/ml、肌醇0.01-0.05mg/ml、烟酰胺0.001-0.005mg/ml、氯化胆碱0.001-0.005mg/ml、异亮氨酸0.01-0.1mg/ml、盐酸吡哆醇0.001-0.005mg/ml、门冬酰胺0.01-0.1mg/ml,余量为胎牛血清。
进一步,所述细胞保存液的成分由以下组分组成:
IL-2,15-25U/ml,羟乙基淀粉12-14mg/ml,,氯化钠1-8mg/ml,氯化镁0.2-0.4mg/ml;人血白蛋白2-6mg/ml、胱氨酸二盐酸盐0.03-0.08mg/ml、α-1,4葡聚糖0.8-1.2mg/ml、无水硫酸镁0.01-0.05mg/ml、无水磷酸二氢钠0.3-0.7mg/ml、氯化钾0.1-0.7mg/ml、葡萄糖2-4mg/ml、还原谷胱甘肽0.004-0.008mg/ml、谷氨酰胺0.1-0.5mg/ml、柠檬酸钠1-6mg/ml、精氨酸0.1-0.5mg/ml、门冬氨酸0.01-0.05mg/ml、谷氨酸0.01-0.05mg/ml、甘氨酸0.01-0.05mg/ml、组氨酸0.01-0.05mg/ml、羟脯氨酸0.01-0.05mg/ml、亮氨酸0.04-0.08mg/ml、核黄素0.001-0.005mg/ml、盐酸硫胺素0.001-0.005mg/ml、维生素B 120.001mg/ml、赖氨酸盐酸盐0.02-0.08mg/ml、甲硫氨酸0.01-0.05mg/ml、苯丙氨酸0.01-0.05mg/ml、脯氨酸0.01-0.05mg/ml、丝氨酸0.01-0.05mg/ml、苏氨酸0.01-0.05mg/ml、色氨酸0.01mg/ml、酪氨酸0.01-0.05mg/ml、缬氨酸0.01-0.05mg/ml、对氨基苯甲酸0.01mg/ml、硝酸钙0.1-0.5mg/ml、生物素0.002-0.005mg/ml、泛酸钙0.005mg/ml、叶酸0.01-0.05mg/ml、肌醇0.01-0.05mg/ml、烟酰胺0.005mg/ml、氯化胆碱0.005mg/ml、异亮氨酸0.03-0.08mg/ml、盐酸吡哆醇0.005mg/ml、门冬酰胺0.03-0.07mg/ml,余量为胎牛血清。
进一步,所述细胞保存液的成分由以下组分组成:
IL-2,20U/ml,羟乙基淀粉13mg/ml,,氯化钠5mg/ml,氯化镁0.3mg/ml;人血白蛋白4mg/ml、胱氨酸二盐酸盐0.05mg/ml、α-1,4葡聚糖1mg/ml、无水硫酸镁0.03mg/ml、无水磷酸二氢钠0.5mg/ml、氯化钾0.4mg/ml、葡萄糖3mg/ml、还原谷胱甘肽0.006mg/ml、谷氨酰胺0.3mg/ml、柠檬酸钠4mg/ml、精氨酸0.3mg/ml、门冬氨酸0.03mg/ml、谷氨酸0.03mg/ml、甘氨酸0.04mg/ml、组氨酸0.03mg/ml、羟脯氨酸0.03mg/ml、亮氨酸0.06mg/ml、核黄素0.003mg/ml、盐酸硫胺素0.003mg/ml、维生素B 120.001mg/ml、赖氨酸盐酸盐0.05mg/ml、甲硫氨酸0.03mg/ml、苯丙氨酸0.03mg/ml、脯氨酸0.03mg/ml、丝氨酸0.04mg/ml、苏氨酸0.03mg/ml、色氨酸0.01mg/ml、酪氨酸0.04mg/ml、缬氨酸0.03mg/ml、对氨基苯甲酸0.01mg/ml、硝酸钙0.3mg/ml、生物素0.003mg/ml、泛酸钙0.005mg/ml、叶酸0.03mg/ml、肌醇0.02mg/ml、烟酰胺0.005mg/ml、氯化胆碱0.005mg/ml、异亮氨酸0.05mg/ml、盐酸吡哆醇0.005mg/ml、门冬酰胺0.04mg/ml,余量为胎牛血清。
本发明还提供一种上述的细胞保存液在保存免疫细胞中的应用。
本发明具有如下技术效果:本发明的细胞保存液针对免疫细胞的特性研发,可以有效的保存免疫细胞。
为让本发明的上述和其它目的、特征和优点能更明显易懂,下文特举较佳实施例,作详细说明如下。
具体实施方式
实施例1
一种特别适于保存免疫细胞的细胞保存液,包括以下成分:
IL-2,20U/ml,羟乙基淀粉13mg/ml,,氯化钠5mg/ml,氯化镁0.3mg/ml;人血白蛋白4mg/ml、胱氨酸二盐酸盐0.05mg/ml、α-1,4葡聚糖1mg/ml、无水硫酸镁0.03mg/ml、无水磷酸二氢钠0.5mg/ml、氯化钾0.4mg/ml、葡萄糖3mg/ml、还原谷胱甘肽0.006mg/ml、谷氨酰胺0.3mg/ml、柠檬酸钠4mg/ml、精氨酸0.3mg/ml、门冬氨酸0.03mg/ml、谷氨酸0.03mg/ml、甘氨酸0.04mg/ml、组氨酸0.03mg/ml、羟脯氨酸0.03mg/ml、亮氨酸0.06mg/ml、核黄素0.003mg/ml、盐酸硫胺素0.003mg/ml、维生素B 120.001mg/ml、赖氨酸盐酸盐0.05mg/ml、甲硫氨酸0.03mg/ml、苯丙氨酸0.03mg/ml、脯氨酸0.03mg/ml、丝氨酸0.04mg/ml、苏氨酸0.03mg/ml、色氨酸0.01mg/ml、酪氨酸0.04mg/ml、缬氨酸0.03mg/ml、对氨基苯甲酸0.01mg/ml、硝酸钙0.3mg/ml、生物素0.003mg/ml、泛酸钙0.005mg/ml、叶酸0.03mg/ml、肌醇0.02mg/ml、烟酰胺0.005mg/ml、氯化胆碱0.005mg/ml、异亮氨酸0.05mg/ml、盐酸吡哆醇0.005mg/ml、门冬酰胺0.04mg/ml,余量为胎牛血清。
实施例2
一种细胞保存液,包括以下成分:
IL-2,10U/ml,羟乙基淀粉20mg/ml,氯化钠10mg/ml,氯化镁0.1mg/ml,余量为胎牛血清。
实施例3
一种细胞保存液,包括以下成分:
IL-2,15U/ml,羟乙基淀粉1,2mg/ml,,氯化钠6mg/ml,氯化镁0.3mg/ml;人血白蛋白0.5mg/ml、胱氨酸二盐酸盐0.04mg/ml、α-1,4葡聚糖0.9mg/ml、无水硫酸镁0.03mg/ml、无水磷酸二氢钠0.7mg/ml、氯化钾0.4mg/ml、葡萄糖3.4mg/ml、还原谷胱甘肽0.008mg/ml、谷氨酰胺0.32mg/ml、柠檬酸钠0.22mg/ml、精氨酸0.34mg/ml、门冬氨酸0.03mg/ml、谷氨酸0.03mg/ml、甘氨酸0.02mg/ml、组氨酸0.02mg/ml、羟脯氨酸0.03mg/ml、亮氨酸0.06mg/ml、核黄素0.003mg/ml、盐酸硫胺素0.003mg/ml、维生素B 120.0004mg/ml、赖氨酸盐酸盐0.04mg/ml、甲硫氨酸0.02mg/ml、苯丙氨酸0.03mg/ml、脯氨酸0.03mg/ml、丝氨酸0.03mg/ml、苏氨酸0.03mg/ml、色氨酸0.006mg/ml、酪氨酸0.03mg/ml、缬氨酸0.03mg/ml、对氨基苯甲酸0.006mg/ml、硝酸钙0.32mg/ml、生物素0.003mg/ml、泛酸钙0.003mg/ml、叶酸0.03mg/ml、肌醇0.02mg/ml、烟酰胺0.004mg/ml、氯化胆碱0.002mg/ml、异亮氨酸0.05mg/ml、盐酸吡哆醇0.003mg/ml、门冬酰胺0.04mg/ml,余量为胎牛血清。
本发明虽然已以较佳实施例公开如上,但其并不是用来限定本发明,任何本领域技术人员在不脱离本发明的精神和范围内,都可以利用上述揭示的方法和技术内容对本发明技术方案做出可能的变动和修改,因此,凡是未脱离本发明技术方案的内容,依据本发明的技术实质对以上实施例所做的任何简单修改、等同变化及修饰,均属于本发明技术方案的保护。
Claims (6)
1.一种细胞保存液,其特征在于,所述细胞保存液包括以下成分:
IL-2,10-30U/ml,
羟乙基淀粉5-20mg/ml,
氯化钠0.3-10mg/ml,
氯化镁0.1-0.5mg/ml,
余量为胎牛血清。
2.根据权利要求1所述的细胞保存液,其特征在于,所述细胞保存液还包括以下成分:
人血白蛋白0-8mg/ml、胱氨酸二盐酸盐0-0.1mg/ml、α-1,4葡聚糖0-1.5mg/ml、无水硫酸镁0-0.05mg/ml、无水磷酸二氢钠0.2-1mg/ml、氯化钾0-0.8mg/ml、葡萄糖0.2-5mg/ml、还原谷胱甘肽0-0.01mg/ml、谷氨酰胺0-0.5mg/ml、柠檬酸钠0-6mg/ml、精氨酸0-0.5mg/ml、门冬氨酸0-0.05mg/ml、谷氨酸0-0.05mg/ml、甘氨酸0-0.05mg/ml、组氨酸0-0.05mg/ml、羟脯氨酸0-0.05mg/ml、亮氨酸0-0.1mg/ml、核黄素0-0.005mg/ml、盐酸硫胺素0-0.005mg/ml、维生素B 120-0.001mg/ml、赖氨酸盐酸盐0-0.1mg/ml、甲硫氨酸0-0.05mg/ml、苯丙氨酸0-0.05mg/ml、脯氨酸0-0.05mg/ml、丝氨酸0-0.05mg/ml、苏氨酸0-0.05mg/ml、色氨酸0-0.01mg/ml、酪氨酸0-0.05mg/ml、缬氨酸0-0.05mg/ml、对氨基苯甲酸0-0.01mg/ml、硝酸钙0-0.5mg/ml、生物素0-0.005mg/ml、泛酸钙0-0.005mg/ml、叶酸0-0.05mg/ml、肌醇0-0.05mg/ml、烟酰胺0-0.005mg/ml、氯化胆碱0-0.005mg/ml、异亮氨酸0-0.1mg/ml、盐酸吡哆醇0-0.005mg/ml、门冬酰胺0-0.1mg/ml。
3.根据权利要求2所述的细胞保存液,其特征在于,所述细胞保存液的成分由以下组分组成:
IL-2,10-30U/ml,羟乙基淀粉10-15mg/ml,氯化钠0.3-10mg/ml,氯化镁0.1-0.5mg/ml;人血白蛋白0.01-8mg/ml、胱氨酸二盐酸盐0.01-0.1mg/ml、α-1,4葡聚糖0.01-1.5mg/ml、无水硫酸镁0.01-0.05mg/ml、无水磷酸二氢钠0.2-1mg/ml、氯化钾0.01-0.8mg/ml、葡萄糖0.2-5mg/ml、还原谷胱甘肽0.001-0.01mg/ml、谷氨酰胺0.01-0.5mg/ml、柠檬酸钠0.01-6mg/ml、精氨酸0.01-0.5mg/ml、门冬氨酸0.01-0.05mg/ml、谷氨酸0.01-0.05mg/ml、甘氨酸0.01-0.05mg/ml、组氨酸0.01-0.05mg/ml、羟脯氨酸0.01-0.05mg/ml、亮氨酸0.01-0.1mg/ml、核黄素0.001-0.005mg/ml、盐酸硫胺素0.001-0.005mg/ml、维生素B 120.0001-0.001mg/ml、赖氨酸盐酸盐0.01-0.1mg/ml、甲硫氨酸0.01-0.05mg/ml、苯丙氨酸0.01-0.05mg/ml、脯氨酸0.01-0.05mg/ml、丝氨酸0.01-0.05mg/ml、苏氨酸0.01-0.05mg/ml、色氨酸0.001-0.01mg/ml、酪氨酸0.01-0.05mg/ml、缬氨酸0.01-0.05mg/ml、对氨基苯甲酸0.001-0.01mg/ml、硝酸钙0.01-0.5mg/ml、生物素0.001-0.005mg/ml、泛酸钙0.001-0.005mg/ml、叶酸0.01-0.05mg/ml、肌醇0.01-0.05mg/ml、烟酰胺0.001-0.005mg/ml、氯化胆碱0.001-0.005mg/ml、异亮氨酸0.01-0.1mg/ml、盐酸吡哆醇0.001-0.005mg/ml、门冬酰胺0.01-0.1mg/ml,余量为胎牛血清。
4.根据权利要求3所述的细胞保存液,其特征在于,所述细胞保存液的成分由以下组分组成:
IL-2,15-25U/ml,羟乙基淀粉12-14mg/ml,氯化钠1-8mg/ml,氯化镁0.2-0.4mg/ml;人血白蛋白2-6mg/ml、胱氨酸二盐酸盐0.03-0.08mg/ml、α-1,4葡聚糖0.8-1.2mg/ml、无水硫酸镁0.01-0.05mg/ml、无水磷酸二氢钠0.3-0.7mg/ml、氯化钾0.1-0.7mg/ml、葡萄糖2-4mg/ml、还原谷胱甘肽0.004-0.008mg/ml、谷氨酰胺0.1-0.5mg/ml、柠檬酸钠1-6mg/ml、精氨酸0.1-0.5mg/ml、门冬氨酸0.01-0.05mg/ml、谷氨酸0.01-0.05mg/ml、甘氨酸0.01-0.05mg/ml、组氨酸0.01-0.05mg/ml、羟脯氨酸0.01-0.05mg/ml、亮氨酸0.04-0.08mg/ml、核黄素0.001-0.005mg/ml、盐酸硫胺素0.001-0.005mg/ml、维生素B 120.001mg/ml、赖氨酸盐酸盐0.02-0.08mg/ml、甲硫氨酸0.01-0.05mg/ml、苯丙氨酸0.01-0.05mg/ml、脯氨酸0.01-0.05mg/ml、丝氨酸0.01-0.05mg/ml、苏氨酸0.01-0.05mg/ml、色氨酸0.01mg/ml、酪氨酸0.01-0.05mg/ml、缬氨酸0.01-0.05mg/ml、对氨基苯甲酸0.01mg/ml、硝酸钙0.1-0.5mg/ml、生物素0.002-0.005mg/ml、泛酸钙0.005mg/ml、叶酸0.01-0.05mg/ml、肌醇0.01-0.05mg/ml、烟酰胺0.005mg/ml、氯化胆碱0.005mg/ml、异亮氨酸0.03-0.08mg/ml、盐酸吡哆醇0.005mg/ml、门冬酰胺0.03-0.07mg/ml,余量为胎牛血清。
5.根据权利要求4所述的细胞保存液,其特征在于,所述细胞保存液的成分由以下组分组成:
IL-2,20U/ml,羟乙基淀粉13mg/ml,氯化钠5mg/ml,氯化镁0.3mg/ml;人血白蛋白4mg/ml、胱氨酸二盐酸盐0.05mg/ml、α-1,4葡聚糖1mg/ml、无水硫酸镁0.03mg/ml、无水磷酸二氢钠0.5mg/ml、氯化钾0.4mg/ml、葡萄糖3mg/ml、还原谷胱甘肽0.006mg/ml、谷氨酰胺0.3mg/ml、柠檬酸钠4mg/ml、精氨酸0.3mg/ml、门冬氨酸0.03mg/ml、谷氨酸0.03mg/ml、甘氨酸0.04mg/ml、组氨酸0.03mg/ml、羟脯氨酸0.03mg/ml、亮氨酸0.06mg/ml、核黄素0.003mg/ml、盐酸硫胺素0.003mg/ml、维生素B 120.001mg/ml、赖氨酸盐酸盐0.05mg/ml、甲硫氨酸0.03mg/ml、苯丙氨酸0.03mg/ml、脯氨酸0.03mg/ml、丝氨酸0.04mg/ml、苏氨酸0.03mg/ml、色氨酸0.01mg/ml、酪氨酸0.04mg/ml、缬氨酸0.03mg/ml、对氨基苯甲酸0.01mg/ml、硝酸钙0.3mg/ml、生物素0.003mg/ml、泛酸钙0.005mg/ml、叶酸0.03mg/ml、肌醇0.02mg/ml、烟酰胺0.005mg/ml、氯化胆碱0.005mg/ml、异亮氨酸0.05mg/ml、盐酸吡哆醇0.005mg/ml、门冬酰胺0.04mg/ml。
6.一种如权利要求1至5中任意一项所述的细胞保存液在保存免疫细胞中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611046215.2A CN107047536A (zh) | 2016-11-22 | 2016-11-22 | 一种细胞保存液及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611046215.2A CN107047536A (zh) | 2016-11-22 | 2016-11-22 | 一种细胞保存液及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107047536A true CN107047536A (zh) | 2017-08-18 |
Family
ID=59619310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611046215.2A Pending CN107047536A (zh) | 2016-11-22 | 2016-11-22 | 一种细胞保存液及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107047536A (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107624753A (zh) * | 2017-09-19 | 2018-01-26 | 北京瑞格瑞特生物科技有限公司 | 一种细胞低氧稳压运输方法 |
CN107970258A (zh) * | 2017-11-20 | 2018-05-01 | 英普乐孚生物技术(上海)有限公司 | 一种嵌合抗原受体t细胞制剂 |
CN108244096A (zh) * | 2018-01-10 | 2018-07-06 | 暨赛再生医学科技有限公司 | 一种长期保存过表达vegf的血管内皮祖细胞的保存液 |
CN110511910A (zh) * | 2019-09-12 | 2019-11-29 | 河北医科大学第一医院 | 一种LncRNA MALAT1的表达上调剂及其应用 |
CN112056309A (zh) * | 2020-11-16 | 2020-12-11 | 广州杜德生物科技有限公司 | 一种细胞保存液及其在保存脐血nk细胞中的应用 |
CN113925049A (zh) * | 2021-12-17 | 2022-01-14 | 广东乾晖生物科技有限公司 | 一种保持细胞活性的细胞保存液及其制备方法和应用 |
CN114451401A (zh) * | 2022-01-21 | 2022-05-10 | 深圳市茵冠生物科技有限公司 | 一种细胞冻存液及其制备方法和应用 |
CN114600869A (zh) * | 2022-03-14 | 2022-06-10 | 北京益华生物科技有限公司 | 一种细胞运输保存液及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1944360A1 (en) * | 2007-01-12 | 2008-07-16 | Koyo International Holding Corporation | Method for culturing dendritic cells (DC) and cytokine-induced killer cells (D-CIK) and applications thereof |
CN101247720A (zh) * | 2005-07-01 | 2008-08-20 | 赛特耐特两合公司 | 细胞贮藏介质 |
CN105524880A (zh) * | 2016-01-27 | 2016-04-27 | 上海润泉生物技术有限公司 | 一种免疫细胞库的构建方法 |
CN105638642A (zh) * | 2016-01-27 | 2016-06-08 | 上海润泉生物技术有限公司 | 一种免疫细胞冻存液及其应用 |
CN105994253A (zh) * | 2016-07-15 | 2016-10-12 | 广州姿生生物科技有限公司 | 一种免疫细胞冻存液 |
-
2016
- 2016-11-22 CN CN201611046215.2A patent/CN107047536A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101247720A (zh) * | 2005-07-01 | 2008-08-20 | 赛特耐特两合公司 | 细胞贮藏介质 |
EP1944360A1 (en) * | 2007-01-12 | 2008-07-16 | Koyo International Holding Corporation | Method for culturing dendritic cells (DC) and cytokine-induced killer cells (D-CIK) and applications thereof |
CN105524880A (zh) * | 2016-01-27 | 2016-04-27 | 上海润泉生物技术有限公司 | 一种免疫细胞库的构建方法 |
CN105638642A (zh) * | 2016-01-27 | 2016-06-08 | 上海润泉生物技术有限公司 | 一种免疫细胞冻存液及其应用 |
CN105994253A (zh) * | 2016-07-15 | 2016-10-12 | 广州姿生生物科技有限公司 | 一种免疫细胞冻存液 |
Non-Patent Citations (1)
Title |
---|
无: "RPMI-1640培养基", 《HTTPS://BAIKE.BAIDU.COM/HISTORY/RPMI-1640%E5%9F%B9%E5%85%BB%E5%9F%BA/4081888/19613541》 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107624753A (zh) * | 2017-09-19 | 2018-01-26 | 北京瑞格瑞特生物科技有限公司 | 一种细胞低氧稳压运输方法 |
CN107970258A (zh) * | 2017-11-20 | 2018-05-01 | 英普乐孚生物技术(上海)有限公司 | 一种嵌合抗原受体t细胞制剂 |
CN107970258B (zh) * | 2017-11-20 | 2020-11-10 | 英普乐孚生物技术(上海)有限公司 | 一种嵌合抗原受体t细胞制剂 |
CN108244096A (zh) * | 2018-01-10 | 2018-07-06 | 暨赛再生医学科技有限公司 | 一种长期保存过表达vegf的血管内皮祖细胞的保存液 |
CN108244096B (zh) * | 2018-01-10 | 2019-01-04 | 暨赛再生医学科技有限公司 | 一种长期保存过表达vegf的血管内皮祖细胞的保存液 |
CN110511910A (zh) * | 2019-09-12 | 2019-11-29 | 河北医科大学第一医院 | 一种LncRNA MALAT1的表达上调剂及其应用 |
CN110511910B (zh) * | 2019-09-12 | 2021-08-20 | 河北医科大学第一医院 | 一种LncRNA MALAT1的表达上调剂及其应用 |
CN112056309A (zh) * | 2020-11-16 | 2020-12-11 | 广州杜德生物科技有限公司 | 一种细胞保存液及其在保存脐血nk细胞中的应用 |
CN113925049A (zh) * | 2021-12-17 | 2022-01-14 | 广东乾晖生物科技有限公司 | 一种保持细胞活性的细胞保存液及其制备方法和应用 |
CN113925049B (zh) * | 2021-12-17 | 2022-04-29 | 广东乾晖生物科技有限公司 | 一种保持细胞活性的细胞保存液及其制备方法和应用 |
CN114451401A (zh) * | 2022-01-21 | 2022-05-10 | 深圳市茵冠生物科技有限公司 | 一种细胞冻存液及其制备方法和应用 |
CN114600869A (zh) * | 2022-03-14 | 2022-06-10 | 北京益华生物科技有限公司 | 一种细胞运输保存液及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107047536A (zh) | 一种细胞保存液及其应用 | |
Zhang et al. | Impacts of heat stress on meat quality and strategies for amelioration: a review | |
Yi et al. | Dietary N-acetylcysteine supplementation alleviates liver injury in lipopolysaccharide-challenged piglets | |
US20080075710A1 (en) | Herbal composition for treating hangovers | |
CN101791327B (zh) | 包含蜂毒和药物粗提物的天然抗生素及其制备方法 | |
CN101371142A (zh) | 诊断方法和治疗方法 | |
ZhENG-RoNG et al. | Effects of the combination of hyperbaric oxygen and 5-fluorouracil on proliferation and metastasis of human nasopharyngeal carcinoma CNE-2Z cells | |
CN103275181A (zh) | 一种金枪鱼碎肉多肽类血管生成抑制因子及其制备方法和用途 | |
Hashemifesharaki et al. | Future nutrient-dense diets rich in vitamin D: a new insight toward the reduction of adverse impacts of viral infections similar to COVID-19 | |
Verma et al. | Attenuation of ROS-mediated myocardial ischemia–reperfusion injury by morin via regulation of RISK/SAPK pathways | |
US7357933B2 (en) | Sporoderm-broken germination-activated ganoderma lucidum spores for protection of dopaminergic neurons and treatment of Parkinson's disease | |
CN113826911A (zh) | 一种适用于运动后恢复疲劳的营养组合物及制备方法 | |
Nagar | Protective effect of glutathione against isoproterenol induced myocardial injury in rats | |
Ibrahim et al. | Alleviating transport stress of broiler using vitamin C and acetyl salicylic acid | |
Liu et al. | Antioxidative effects of tetramethylpyrazine on acute ethanol-induced lipid peroxidation | |
Gao et al. | Effects of acute administration of ethanol on experimental arrhythmia | |
Umar et al. | The effect of aqueous extracts of Hibiscus sabdariffa (Sorrel) calyces on heamatological profile and organ pathological changes in Trypanasoma congolense–infected rat | |
KR100814351B1 (ko) | 담자균류 및 두릅나무과 추출물의 생리학적 활성 조성물 | |
EP3335718B1 (en) | Chinese medicine hangover curing agent | |
CN104106826B (zh) | 一种红景天饮料及其制备方法 | |
Rosas-Arreguín et al. | Bursera fagaroides, effect of an ethanolic extract on ornithine decarboxylase (ODC) activity in vitro and on the growth of Entamoeba histolytica | |
Carbajo | OSMOLYTES IN THE TREATMENT OF CORONAVIRUSES. Methylation hypothesis (BETACH3) | |
CN104939087A (zh) | 一种保健食品配方及其制备方法 | |
CN106261265B (zh) | 一种淫羊藿抗疲劳运动饮料及其制备方法 | |
JiPing | Effect of aqueous extract of Lycium barbarum on serum CK, CK-MB activities and myocardium injury in exhausted swimming rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170818 |